Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Staidson (Beijing) Biopharmaceuticals Co Net Margin % Related Terms
Staidson (Beijing) Biopharmaceuticals Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staidson (Beijing) Biopharmaceuticals Co Net Margin % Chart
Staidson (Beijing) Biopharmaceuticals Co Annual Data
SZSE:300204 vs VRTX, REGN, MRNA: Net Margin % Comparison
For the Biotechnology subindustry, Staidson (Beijing) Biopharmaceuticals Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Staidson (Beijing) Biopharmaceuticals Co Net Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) has a Net Margin % of -61.60% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Staidson (Beijing) Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Staidson (Beijing) Biopharmaceuticals Co ranks #433 out of 948 companies in the Biotechnology industry, placing it in the top 45.7%.
Is Staidson (Beijing) Biopharmaceuticals Co's Net Margin % too high?
Staidson (Beijing) Biopharmaceuticals Co's current Net Margin % is -61.60%. Based on the distribution chart, Staidson (Beijing) Biopharmaceuticals Co ranks #433 out of 948 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Staidson (Beijing) Biopharmaceuticals Co has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Staidson (Beijing) Biopharmaceuticals Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Staidson (Beijing) Biopharmaceuticals Co ranks #433 out of 948 companies for Net Margin %. This puts Staidson (Beijing) Biopharmaceuticals Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Staidson (Beijing) Biopharmaceuticals Co and its competitors. Staidson (Beijing) Biopharmaceuticals Co's current Net Margin % is -61.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staidson (Beijing) Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.34, compared to a current price of ¥20.94 — trading 382.5% above its estimated fair value. The current Net Margin % is -61.60%. Staidson (Beijing) Biopharmaceuticals Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204), the current Net Margin % is -61.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Overvalued in 2026?
Based on GuruFocus' analysis, Staidson (Beijing) Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥20.94 is trading 382.5% above its estimated GF Value™ of ¥4.34.
GuruFocus considers Staidson (Beijing) Biopharmaceuticals Co to be Significantly Overvalued.
Key valuation signals for SZSE:300204:
Net Margin %: -61.60%
GF Value™: ¥4.34 vs. price of ¥20.94 (382.5% above fair value)
No single metric tells the full story. See the SZSE:300204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
46GF Score
Get the complete analysis for SZSE:300204
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300204 has been successfully added to your 
